GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » YoY Rev. per Sh. Growth

Albireo Pharma (FRA:BDQM) YoY Rev. per Sh. Growth : 219.62% (As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Albireo Pharma's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2022 was 219.62%.

Albireo Pharma's Revenue per Share for the three months ended in Sep. 2022 was €0.51.


Albireo Pharma YoY Rev. per Sh. Growth Historical Data

The historical data trend for Albireo Pharma's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma YoY Rev. per Sh. Growth Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -27.17 -38.74 337.47

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.39 1,175.21 272.09 277.14 219.62

Albireo Pharma YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Albireo Pharma's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2021 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2021 )
=(Revenue per Share (A: Dec. 2021 )-Revenue per Share (A: Dec. 2020 ))/ | Revenue per Share (A: Dec. 2020 ) |
=(1.868-0.427)/ | 0.427 |
=337.47 %

Albireo Pharma's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2022 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2022 )
=(Revenue per Share (Q: Sep. 2022 )-Revenue per Share (Q: Sep. 2021 )) / | Revenue per Share (Q: Sep. 2021 )) |
=(0.505-0.158)/ | 0.158 |
=219.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albireo Pharma YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines